TABLE 1.
GSTM1+ | GSTM1− | |
Male/female | 5/14 | 7/11 |
Age | 29.8 ± 7.5 (20–43) | 28 ± 6.1 (20–42) |
Race | ||
Northern European ancestry | 15 | 18 |
African American ancestry | 4 | 0 |
Family history of atopy | 19 | 18 |
Baseline spirometry | ||
FVC, L | 4.1 ± 0.4 (3.38–4.7) | 4.9 ± 1.0 (3.5–6.5) |
FVC, % predicted | 98.7 ± 9.9 (81–120) | 111.9 ± 17.9 (90–121) |
FEV1, L | 3.15 ± 0.52 (2.6–3.9) | 3.65 ± 0.64 (2.84–4.7) |
FEV1, % predicted | 84.6 ± 12.3 (65–111) | 94.9 ± 12.5 (77–122) |
Treatment (regular or as needed) | ||
Albuterol inhaler | 19 | 18 |
Long-acting bronchodilator | 2 | 2 |
Inhaled corticosteroids | 3 | 2 |
Nasal corticosteroids | 2 | 1 |
Montelukast | 1 | 4 |
Antihistamines | 6 | 9 |
Allergen used for challenge | ||
Dust mite | 6 | 4 |
Cat | 7 | 10 |
Ragweed | 2 | 1 |
Bermuda grass | 1 | 1 |
Bluegrass | 1 | 1 |
Rye grass | 1 | 1 |
Timothy grass | 1 | 0 |
Data are presented as count or mean ± SD (range).